(Q37698197)

22 August 2017

1 reference

title

Interleukin-6 as a therapeutic target in candidate inflammatory diseases (English)

1 reference

22 August 2017

0 references

0 references

N Nishimoto

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

24 February 2010

1 reference

Clinical Pharmacology & Therapeutics

22 August 2017

published in

1 reference

22 August 2017

volume

87

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

483-487

1 reference

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Interleukin-6: from basic science to medicine--40 years in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Clinical value of blocking IL-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

TH17 cells in development: an updated view of their molecular identity and genetic programming

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Targeting interleukin-6 in pediatric rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.313

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.313

1 reference

22 August 2017

1 reference